BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 28074573)

  • 1. Structural, Functional, and Clinical Characterization of a Novel PTPN11 Mutation Cluster Underlying Noonan Syndrome.
    Pannone L; Bocchinfuso G; Flex E; Rossi C; Baldassarre G; Lissewski C; Pantaleoni F; Consoli F; Lepri F; Magliozzi M; Anselmi M; Delle Vigne S; Sorge G; Karaer K; Cuturilo G; Sartorio A; Tinschert S; Accadia M; Digilio MC; Zampino G; De Luca A; Cavé H; Zenker M; Gelb BD; Dallapiccola B; Stella L; Ferrero GB; Martinelli S; Tartaglia M
    Hum Mutat; 2017 Apr; 38(4):451-459. PubMed ID: 28074573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome.
    Martinelli S; Nardozza AP; Delle Vigne S; Sabetta G; Torreri P; Bocchinfuso G; Flex E; Venanzi S; Palleschi A; Gelb BD; Cesareni G; Stella L; Castagnoli L; Tartaglia M
    J Biol Chem; 2012 Aug; 287(32):27066-77. PubMed ID: 22711529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
    Fragale A; Tartaglia M; Wu J; Gelb BD
    Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenic PTPN11 variants involving the poly-glutamine Gln
    Martinelli S; Pannone L; Lissewski C; Brinkmann J; Flex E; Schanze D; Calligari P; Anselmi M; Pantaleoni F; Canale VC; Radio FC; Ioannides A; Rahner N; Schanze I; Josifova D; Bocchinfuso G; Ryten M; Stella L; Tartaglia M; Zenker M
    Hum Mutat; 2020 Jun; 41(6):1171-1182. PubMed ID: 32112654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.
    Tartaglia M; Kalidas K; Shaw A; Song X; Musat DL; van der Burgt I; Brunner HG; Bertola DR; Crosby A; Ion A; Kucherlapati RS; Jeffery S; Patton MA; Gelb BD
    Am J Hum Genet; 2002 Jun; 70(6):1555-63. PubMed ID: 11992261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SHP2 sails from physiology to pathology.
    Tajan M; de Rocca Serra A; Valet P; Edouard T; Yart A
    Eur J Med Genet; 2015 Oct; 58(10):509-25. PubMed ID: 26341048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes.
    Martinelli S; Torreri P; Tinti M; Stella L; Bocchinfuso G; Flex E; Grottesi A; Ceccarini M; Palleschi A; Cesareni G; Castagnoli L; Petrucci TC; Gelb BD; Tartaglia M
    Hum Mol Genet; 2008 Jul; 17(13):2018-29. PubMed ID: 18372317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compound heterozygosity for PTPN11 variants in a subject with Noonan syndrome provides insights into the mechanism of SHP2-related disorders.
    Lorca R; Pannone L; Cuesta-Llavona E; Bocchinfuso G; Rodríguez-Reguero J; Carpentieri G; Hernando I; Flex E; Tartaglia M; Coto E; Gómez J; Martinelli S
    Clin Genet; 2021 Mar; 99(3):457-461. PubMed ID: 33354767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unveiling the Molecular Basis of the Noonan Syndrome-Causing Mutation T42A of SHP2.
    Toto A; Malagrinò F; Visconti L; Troilo F; Gianni S
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
    Müller PJ; Rigbolt KT; Paterok D; Piehler J; Vanselow J; Lasonder E; Andersen JS; Schaper F; Sobota RM
    J Proteomics; 2013 Jun; 84():132-47. PubMed ID: 23584145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
    Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
    Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13.
    Maheshwari M; Belmont J; Fernbach S; Ho T; Molinari L; Yakub I; Yu F; Combes A; Towbin J; Craigen WJ; Gibbs R
    Hum Mutat; 2002 Oct; 20(4):298-304. PubMed ID: 12325025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of the PTPN11 gene in Egyptian patients with Noonan syndrome.
    Essawi ML; Ismail MF; Afifi HH; Kobesiy MM; El Kotoury A; Barakat MM
    J Formos Med Assoc; 2013 Nov; 112(11):707-12. PubMed ID: 24183200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.
    Tartaglia M; Mehler EL; Goldberg R; Zampino G; Brunner HG; Kremer H; van der Burgt I; Crosby AH; Ion A; Jeffery S; Kalidas K; Patton MA; Kucherlapati RS; Gelb BD
    Nat Genet; 2001 Dec; 29(4):465-8. PubMed ID: 11704759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new mutation in the C-SH2 domain of PTPN11 causes Noonan syndrome with multiple giant cell lesions.
    Carapito R; Paul N; Untrau M; Ott L; Corradini N; Poignant S; Geffroy L; Caldagues E; Heymann MF; Cassagnau E; Isidor B; Bahram S
    J Hum Genet; 2014 Jan; 59(1):57-9. PubMed ID: 24225993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors.
    Mutesa L; Pierquin G; Janin N; Segers K; Thomée C; Provenzi M; Bours V
    Cancer Genet Cytogenet; 2008 Apr; 182(1):40-2. PubMed ID: 18328949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
    Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
    Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.
    Niihori T; Aoki Y; Ohashi H; Kurosawa K; Kondoh T; Ishikiriyama S; Kawame H; Kamasaki H; Yamanaka T; Takada F; Nishio K; Sakurai M; Tamai H; Nagashima T; Suzuki Y; Kure S; Fujii K; Imaizumi M; Matsubara Y
    J Hum Genet; 2005; 50(4):192-202. PubMed ID: 15834506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetics and variation in phenotype in Noonan syndrome.
    Jongmans M; Otten B; Noordam K; van der Burgt I
    Horm Res; 2004; 62 Suppl 3():56-9. PubMed ID: 15539800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
    Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
    Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.